Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1761918 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $17.72Day −2.42%Mkt cap $5.5B1Y +1043.2%Off 52W high −27.0%Vol (1Y) 105.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,260 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.9% of sh out |
| Days to cover5.9d |
| 13F net flow (QoQ)+8.15% |
| Top-10 13F concentration56.6% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$277.0M |
| ROE−33.3% |
| ROIC−36.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+376.3% |
| 1Y+1043.2% |
| 3Y+571.2% |
| 5Y−15.6% |
| Since incept. (ann.)−0.2% |
Total return through 2026-07-29 · series begins 2021-07-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)105.9% |
| Ann. volatility (3Y)88.5% |
| Sharpe (1Y)2.81 |
| Sharpe (3Y)1.18 |
| Max drawdown (1Y)−59.5% |
| Max drawdown (3Y)−67.7% |
| Beta (3Y vs SPY)−0.42 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24.7M | $399M | 7.93% | +8.6% |
| T. Rowe Price Investment Management, Inc. | 21.3M | $344M | 6.84% | +1.7% |
| BlackRock, Inc. | 20.2M | $326M | 6.48% | +29.2% |
| Venrock Adviser, LLC | 16.4M | $265M | 5.27% | −8.3% |
| RTW INVESTMENTS, LP | 16.2M | $261M | 5.20% | +10917.4% |
| Vivo Capital, LLC | 12.2M | $197M | 3.91% | +31.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.2M | $182M | 3.62% | new |
| Siren, L.L.C. | 11.2M | $182M | 3.62% | +28.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.60 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$0.11 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.12 | — | — | — |
| 2025-03-31 | 2025-05-13 | −$0.11 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
